95% of patients receiving CVP reported at least one adverse event which was similar to the R-CVP group (97%). These were predominantly associated with the gastrointestinal and nervous systems.
The most common severe adverse events were neutropenia, fatigue and back pain. These occurred at a slightly higher frequency in patients receiving R-CVP than CVP alone.
The incidence of grade 3 or 4 neutropenia was higher during treatment with R-CVP (24%) compared to CVP (14%). There was no difference between groups in the overall infection rate or incidence of neutropenic sepsis.
Following CVP-R, 5 patients experienced a total of 6 life-threatening events. There were, however, no treatment-related deaths.
71% of patients who received CVP-R experienced an adverse event within 24 hours of treatment, compared to 51% in the CVP arm. These adverse events were mostly rituximab-associated reaction.